While recent years have seen scientists make major advances in cutting-edge treatments such as gene and cell therapies, manufacturing remains a significant hurdle. The complex, multi-step processes required are beyond the capabilities of a traditional pharmaceutical plant.
That’s where Resilience comes in. Established by Robert Nelsen, co-founder of the venture firm ARCH Venture Partners, the company began with more than $800 million in capital and an aim to dramatically increase production capacity for innovative medicines. Its board members and advisers include Nobel Laureate Frances Arnold and two former Food and Drug Administration commissioners, Scott Gottlieb and Mark McClellan.
